Karolinska Development – Interim report January - March, webcast and conference call Tuesday, May 15

STOCKHOLM – May 10, 2012. Karolinska Development will publish its interim report for January - March 2012 on Tuesday, May 15, during the day. The company will also host a live webcast and a conference call on the same day at 16.30 CET.

The webcast can be followed live on www.karolinskadevelopment.com or on http://financialhearings.nu/120515/karolinskadevelopment

Participant access numbers: SE: +46 (0) 8 505 597 72, UK: +44 (0) 20 775 099 50 or US : +1 8 666 765 870

Host: Torbjörn Bjerke, CEO

For further information, please contact:

Benjamin Nordin, IRO, Karolinska Development
Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 15 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

About Us

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.

Subscribe

Documents & Links